Author | Targeted Oncology


Targeted Therapy in Early-Stage HER2+ Breast Cancer

July 31, 2020


Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

Advancing Survival in Relapsed/Refractory Multiple Myeloma

July 28, 2020


A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Radioiodine Refractory Differentiated Thyroid Carcinoma

July 13, 2020


A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

Role of Targeted Therapies in Advanced Cholangiocarcinoma

July 10, 2020


Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.